187 related articles for article (PubMed ID: 9137790)
1. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.
Reni M; Ferreri AJ; Garancini MP; Villa E
Ann Oncol; 1997 Mar; 8(3):227-34. PubMed ID: 9137790
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ; Reni M; Villa E
Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.
Reni M; Ferreri AJ; Guha-Thakurta N; Blay JY; Dell'Oro S; Biron P; Hochberg FH
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):419-25. PubMed ID: 11567816
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of treatment of primary CNS lymphoma.
Ferreri AJ; Reni M; Pasini F; Calderoni A; Tirelli U; Pivnik A; Aondio GM; Ferrarese F; Gomez H; Ponzoni M; Borisch B; Berger F; Chassagne C; Iuzzolino P; Carbone A; Weis J; Pedrinis E; Motta T; Jouvet A; Barbui T; Cavalli F; Blay JY
Neurology; 2002 May; 58(10):1513-20. PubMed ID: 12034789
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system (CNS) lymphoma in immunocompetent patients.
Plasswilm L; Herrlinger U; Korfel A; Weller M; Küker W; Kanz L; Thiel E; Bamberg M
Ann Hematol; 2002 Aug; 81(8):415-23. PubMed ID: 12223997
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
9. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
[TBL] [Abstract][Full Text] [Related]
10. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
12. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
13. [Primary CNS lymphoma--an update].
Soussain C; Houillier C; Choquet S; Hoang-Xuan K
Bull Cancer; 2014 Mar; 101(3):314-24. PubMed ID: 24691194
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
Velasco R; Mercadal S; Vidal N; Alañá M; Barceló MI; Ibáñez-Juliá MJ; Bobillo S; Caldú Agud R; García Molina E; Martínez P; Cacabelos P; Muntañola A; García-Catalán G; Sancho JM; Camro I; Lado T; Erro ME; Gómez-Vicente L; Salar A; Caballero AC; Solé-Rodríguez M; Gállego Pérez-Larraya J; Huertas N; Estela J; Barón M; Barbero-Bordallo N; Encuentra M; Dlouhy I; Bruna J; Graus F;
J Neurooncol; 2020 Jul; 148(3):545-554. PubMed ID: 32524392
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
16. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
18. Current management of primary central nervous system lymphoma.
Schultz CJ; Bovi J
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):666-78. PubMed ID: 20159361
[TBL] [Abstract][Full Text] [Related]
19. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
